Biotech and Pharma Industry News | BioPharma Dive
WEBBioAge prices $198M IPO, validating pivot to obesity drug research. The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives.
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Pharma News | BioPharma Dive
WEB4 days ago · The top biopharma conferences in 2025. Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch in 2025. By BioPharma Dive staff • Oct. 1, 2024. News roundup.
Radiopharmaceuticals for cancer: Making radiation precise
WEBAug 15, 2023 · When the Food and Drug Administration approved a new prostate cancer drug last year, it validated a bet made by Novartis to acquire the drug’s maker, Endocyte. The decision was also another step forward for a long-studied research field that appears to finally be coming of age. The medicine, Pluvicto, is known as a “radiopharmaceutical.”.
Novartis wins FDA approval for new heart drug, but faces uphill …
WEBDec 22, 2021 · Novartis priced Leqvio at $3,250 per dose for U.S. sale, meaning the first year of treatment will cost $9,750 and subsequent years $6,500. That’s slightly higher than the $5,400-per-year price that the Institute for Clinical and Economic Review, a watchdog group on drug costs, said would be cost effective for Leqvio when used broadly, but ...
The biopharma industry outlook on 2024: Guarded optimism for a …
WEBPublished Jan. 16, 2024. Ned Pagliarulo Lead Editor. Brian Tucker / BioPharma Dive. Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a ...
BioMarin finally secures FDA approval of hemophilia gene therapy
WEBJun 29, 2023 · The Food and Drug Administration approved on Thursday the first gene therapy for the most common form of hemophilia, clearing the way for what patients, doctors and the medicine’s developer hope could be a one-time treatment for the rare bleeding disorder. BioMarin Pharmaceutical, the California …
Biotech News - BioPharma Dive
WEB4 days ago · With $115M more, Triveni accelerates immune drug work. The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year. By Gwendolyn Wu • Oct. 2, 2024.
Lilly, Boehringer diabetes pill wins expanded use in heart failure
WEBFeb 25, 2022 · The Food and Drug Administration approved expanded use of Eli Lilly and Boehringer Ingleheim’s diabetes drug Jardiance, announcing Thursday that the pill can be used in a broader group of heart failure patients. The FDA cleared the drug for sicker patients, those with weaker heart muscles, in August 2021. The …
Novo’s latest obesity pill spurs major weight loss in small trial
WEBMar 7, 2024 · A newer drug Novo’s working on, CagriSema, helped obese people lose 17% of their body weight at 20 weeks, while an injectable from Viking Therapeutics was associated with 15% weight loss in 13 weeks. A pill Lilly has in Phase 3 testing, meanwhile, hit 13% weight loss at 26 weeks. Structure Therapeutics’ experimental pill produced 5% …